ACC 2022

ACC 2022: PACIFIC AF - Multicenter, Randomized, Active Comparator-Controlled, Double-Blind, Double-Dummy, Parallel Group, Dose-Finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian with Apixaban in Patients with A-Fib

C. Michael Gibson and Manesh Patel discuss the PACIFC-AF trial presented at ACC 2022.

We Recommend